(NASDAQ: CASI) Casi Pharmaceuticals's forecast annual revenue growth rate of 27.86% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Casi Pharmaceuticals's revenue in 2024 is $33,879,000.On average, 1 Wall Street analysts forecast CASI's revenue for 2024 to be $264,887,865, with the lowest CASI revenue forecast at $264,887,865, and the highest CASI revenue forecast at $264,887,865. On average, 1 Wall Street analysts forecast CASI's revenue for 2025 to be $621,817,574, with the lowest CASI revenue forecast at $621,817,574, and the highest CASI revenue forecast at $621,817,574.
In 2026, CASI is forecast to generate $941,154,611 in revenue, with the lowest revenue forecast at $941,154,611 and the highest revenue forecast at $941,154,611.